Business
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022IND submission for CRB-601
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022IND submission for CRB-601 is on track for mid-2023 Expanding oncology pipeline through strategic transactions remains key priorityCash and investments on hand of $67 million funds operations through the second quarter of 2024NORWOOD, Mass., Nov. 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), an oncology company, today provided a corporate update and reported financial results for the third quarter of 2022.\n\n \n \n \n \n \n \n\n \nKey Corporate and Program Updates:\nAnti-integrin monoclonal antibody (mAb) programs targeting the inhibition of TGFβ are progressing on scheduleCRB-601, an anti-αvβ8 mAb, is being developed as a potential treatment for solid tumors.Across models explored to-date, CRB-601 demonstrates an enhancement of anti-tumor activity when combined with anti PD-1 therapy compared to either single agent alone. Latest data to be presented this Thursday at SITC 2022.Data supports the hypothesis that blockade of latent TGFb production by CRB-601 can lead to changes in immune cell infiltration in the tumor microenvironment, potentially enhancing the benefit of PD-1 blockade.IND-enabling activities for CRB-601 are ongoing and the program is on schedule for an IND submission in mid-2023.Recent clinical updates from investigational therapies also targeting latent TGFb reinforce the promise of this novel approach in oncology.CB1 inverse agonist program for obesity / metabolismCRB-913, a novel CB1 inverse agonist with highly differentiated PK from other members of its class, has demonstrated weight loss and improvement in multiple metabolic parameters, as monotherapy and in combination within liraglutide, semaglutide and tirzepatide in animal models of diet-induced obesity.New data was shared in an oral presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) in September 2022. View the presentation here.Data is being prepared for publication.Corbus is actively exploring partnerships to advance CRB-913 into clinical studies.A detailed update on the Corbus pipeline can be found in the most recent Corporate Presentation available on the Company's website here.\"We continue to progress CRB-601 to...